1405 related articles for article (PubMed ID: 19788471)
1. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
2. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation.
Silberstein SD; Berner T; Tobin J; Xiang Q; Campbell JC
Headache; 2009 Oct; 49(9):1283-97. PubMed ID: 19751371
[TBL] [Abstract][Full Text] [Related]
3. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Elkind AH; MacGregor EA
Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529
[TBL] [Abstract][Full Text] [Related]
4. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.
Brandes JL; Poole Ac; Kallela M; Schreiber CP; MacGregor EA; Silberstein SD; Tobin J; Shaw R
Cephalalgia; 2009 Nov; 29(11):1133-48. PubMed ID: 19811503
[TBL] [Abstract][Full Text] [Related]
5. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
Spierings EL; Keywood C
Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
[TBL] [Abstract][Full Text] [Related]
6. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
Marcus DA; Bernstein CD; Sullivan EA; Rudy TE
Headache; 2010 Apr; 50(4):551-62. PubMed ID: 20236337
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
MacGregor EA; Pawsey SP; Campbell JC; Hu X
Gend Med; 2010 Apr; 7(2):88-108. PubMed ID: 20435272
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and tolerability of rizatriptan wafers in migraine.
Cady R; Crawford G; Ahrens S; Hairwassers D; Getson A; Visser WH; Lines C;
MedGenMed; 2001 Jun; 3(3):1. PubMed ID: 11549974
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
12. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
15. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
Visser WH; Winner P; Strohmaier K; Klipfel M; Peng Y; McCarroll K; Cady R; Lewis D; Nett R;
Headache; 2004 Oct; 44(9):891-9. PubMed ID: 15447698
[TBL] [Abstract][Full Text] [Related]
16. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
[TBL] [Abstract][Full Text] [Related]
17. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Wade A; Pawsey S; Whale H; Boyce M; Warrington S
Clin Drug Investig; 2009; 29(5):325-37. PubMed ID: 19366274
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
